Search results for "Highlights"


 
Results 101 - 110 of about 366 for "Highlights".

Highlights

An analysis of patients with insulin-treated diabetes found that 38% of those with late-onset type 1 diabetes did not receive insulin at diagnosis, nearly half of whom reported a type 2 diabetes diagnosis.
May 2019

Highlights

Researchers studied an early intervention model in which an inpatient diabetes team electronically identified patients with hyperglycemia and aimed to provide bedside management within 24 hours of admission, compared with a referral-based
April 2019

Highlights

Sodium-glucose cotransporter-2 (SGLT2) inhibitors were associated with fewer hospitalizations for heart failure and slower progression of kidney disease while glucagon-like peptide-1 (GLP-1) receptor agonists were associated with lower risk of stroke
March 2019

Highlights

Patients with type 1 diabetes and a mean three-year HbA1c level greater than 8.0% had a higher fracture risk than those with a mean three-year HbA1c level of 7.0% or less.
February 2019

Highlights

https://diabetes.acponline.org/archives/2017/12/08/2.htm. The results highlight the potential benefit of targeting individuals with an elevated one-hour blood glucose level and, if supported by ... Our results highlight the potential benefit of targeting
December 2017

Highlights

Patients' perceived helpfulness of certain actions by health care professionals was linked to earlier insulin initiation and greater insulin continuation over time, a survey found.
February 2019

Highlights

The comparison of dipeptidyl peptidase-4 inhibitors with other drug classes did find higher rates of major adverse cardiovascular events with basal insulin, sulfonylureas, and meglitinides than with the newer drugs.
January 2019

Highlights

Sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists had similar rates of other adverse events, including bone fracture, acute kidney injury, serious urinary tract infection, venous thromboembolism, and
December 2018

Highlights

Age, sex, body mass index, peripheral sensory neuropathy, and estimated glomerular filtration rate were the included variables.
December 2018

Highlights

The findings may reassure prescribers of dipeptidyl peptidase-4 inhibitors that the drug class does not significantly increase the risk of adverse pancreatic outcomes compared with other second-line therapies, study authors said.
November 2018

Result Page: Prev   6   7   8   9   10   11   12   13   14   15   Next